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1. Abstract 19 
Introduction: Nano-scale formulations are being developed to improve the delivery of orally 20 
administered medicines, and the interactions between nanoformulations and the 21 
gastrointestinal luminal, mucosal and epithelial environment is currently being investigated. 22 
The mucosal surface of the gastrointestinal tract is capable of trapping and eliminating large 23 
particles and pathogens as part of the natural defences of the body, it is becoming clearer that 24 
nanoformulation properties such as particle size, charge, and shape, as well as mucous 25 
properties such as viscoelasticity, thickness, density, and turn-over time are all relevant to 26 
these interactions. However, progress has been slow to utilise this information to produce 27 
effective mucous-penetrating particles. Areas covered: This review focuses on delivery 28 
method of nanomedicines both into and across the gastrointestinal mucosal surface, and aims 29 
to summarise the biological barriers that exist to successful oral nanomedicine delivery and 30 
how these barriers may be investigated and overcome. Expert commentary: Despite successes 31 
in the laboratory, no nanotechnology-enabled products are currently in clinical use which 32 
either specifically target the intestinal mucous surface or cross the epithelial barrier intact. 33 
New nanomedicine-based treatments of local diseases (intestinal cancer, inflammation, 34 
infection) and systemic diseases are advancing towards clinical use, and offer genuine 35 
opportunities to improve therapy. 36 
 37 
2. Introduction  38 
Oral delivery is currently the most common and the most accepted route of drug 39 
administration used in patient treatment. This is for several reasons, including the 40 
convenience of oral administration, the low degree of invasiveness compared to other routes, 41 
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and the fact that the human intestine is particularly suited for the absorption of small 42 
molecules with certain physiochemical properties. The human intestinal epithelium consists 43 
mostly of enterocytes which express microvilli on the apical exterior, increasing the mean 44 
total mucosal surface of the digestive tract interior to around 32-400 metres2, depending on 45 
the methods used to assess the surface [1,2]. Despite the obvious advantages of intestinal 46 
absorption as a method of drug delivery, there are a number of critical considerations when 47 
attempting to exploit this route. These include i) the stability of the medicine in the luminal 48 
fluid; ii) the drug solubility in the various pH and contents found in the intestinal tract; iii) the 49 
mucous and cell membrane as a barrier for drug absorption; iv) the activities of first pass drug 50 
elimination processes in both the intestine and liver [3]. These issues can often be overcome 51 
by the application of design rules, such as Lipinski’s rule of five (No more than five 52 
hydrogen bond donors, no more than ten hydrogen bond acceptors, a molecular mass less 53 
than 500, a log P of less than 5) and its various iterations. Rational screening of drug 54 
candidates in this way can reduce the attrition inherent in drug development programmes, but 55 
an additional approach is to utilise nanoformulation technologies for improving drug 56 
delivery.  57 
Nanomedicine involves the utilisation of particles or emulsions within the size range of 1-999 58 
nanometres and is being researched to improve drug dissolution, protect drugs from the 59 
luminal environment, release drugs in a more controlled manner, and exploit the various 60 
particle-specific anatomical, physiological and molecular machinery of the gastrointestinal 61 
system [4]. The most promising types of nanoformulations used for drug delivery include the 62 
particle-based systems such as inorganic nanoparticles, solid drug nanoparticles (SDNs), 63 
solid lipid nanopartcles (SLNs), polymeric nanoparticles and dendrimers, and the non-solid-64 
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based systems such as nanoemulsions (NEs), liposomes and micelles [5]. Of note, the only 65 
nanoformulations currently used clinically for oral administration are SDNs.  66 
Targeted oral nanoformulations are being developed which can directly bind to the intestinal 67 
mucous and the epithelial surface for local release of drug, as well as improve the dissolution 68 
of drugs in the gastrointestinal fluid [6-9]. In addition, studies are working to develop orally 69 
administered nanoparticles which can reach the systemic circulation intact. These goals 70 
require radically different strategies to be successful and will encounter specific barriers, 71 
depending on the intended lifespan and end goal of the nanoparticle. This review will focus 72 
on these different biological barriers encountered by nanomedicines following oral 73 
administration. The authors will also investigate into how scientists have attempted to 74 
overcome these barriers, and in some cases how barrier mechanisms have been exploited for 75 
improving the effectiveness of oral nanomedicine delivery. Additionally, the authors have 76 
also briefly assessed the limitations of assessing nanoparticle intestinal absorption using in 77 
vitro methodologies traditionally used for small molecules.  78 
 79 
3. Barriers to the oral absorption of nanoparticles 80 
If an orally administered nanoparticle is to reach the systemic circulation intact, numerous 81 
barriers both physical and chemical must be overcome if the particle is to avoid destruction or 82 
undesirable modification. In sequential order following administration, the barriers that will 83 
be encountered include i) the oral, gastric and intestinal fluid environment; ii) the mucous 84 
surface of the stomach and intestine; iii) the epithelial cells of the intestine (Table 1). If the 85 
target of the nanoparticle is the mucosal surface, as is the case when treating gastric H. pylori 86 
infection, it would not be required for the nanoparticle to be able to traverse the epithelial cell 87 
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layer. Further still, if the purpose of the nanoparticle is to increase the dissolution rate of 88 
poorly soluble drugs then there would be no requirement to design the particles to cross either 89 
mucous or cells. Effectively, the design challenge facing formulation scientists becomes more 90 
complex when nanoparticles are required to overcome additional barriers. This may explain 91 
why all oral nanomedicines currently used in clinical therapy were developed to improve the 92 
dissolution of poorly soluble drugs, as described in Section 6. In Sections 3.1 to 3.3 the 93 
authors describe the physical and chemical properties of each barrier, how these properties 94 
can impede the ability of nanoparticles to reach the systemic circulation, and how scientists 95 
have attempted to overcome these barriers when designing nanoscale delivery systems. 96 
 97 
3.1 The oral, gastric and intestinal fluid environment 98 
Once administered orally, nanoparticles enter a fluid environment which has the potential to 99 
influence the properties of the nanoparticles. Relevant factors include: i) enzymes in the 100 
saliva, stomach fluid and intestine fluid; ii) emulsifiers in bile iii) food components; iv) the 101 
pH environment of the stomach and intestine; v) gut motility; vi) disease state. Although not 102 
easily visualised as a physical barrier to nanoparticle absorption, the fluid environment of the 103 
gastrointestinal system can change rapidly and dramatically, and this may have a significant 104 
knock-on effect on the absorption, toxicity and efficacy of orally-administered nanoparticles. 105 
Many of the excipients present in lipid-containing nanoparticulate systems are esters, and 106 
therefore it is unsurprising to find that these systems can be hydrolysed by the various 107 
lipolytic enzymes in the gastrointestinal fluid [10]. Nanoparticles can be utilised to protect 108 
drugs and macromolecules from intestinal enzymatic degradation. For example, diabetes 109 
treatment using orally-administered insulin is impeded due to intestinal protease activity [11] 110 
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and nanoparticle formulations have been developed to protect the insulin from this 111 
degradation [12,13]. This demonstrates that nanoparticles can be used to improve the 112 
intestinal stability of contained pharmaceutical ingredients, but it is also important to 113 
understand how the nanoparticles themselves are affected by intestinal enzymes, the levels of 114 
which can fluctuate greatly depending on feeding state.  115 
Bile salts are water-soluble, amphipathic end products of cholesterol metabolism. Formed in 116 
the liver, bile acids are excreted into the small intestine via the bile duct and pancreas, where 117 
they help solubilise and promote the absorption of dietary lipids [14]. This process of lipid 118 
solubilisation can also impact on the stability of lipid-containing nanoparticles. When the 119 
objective is keep lipid nanoparticles intact in the intestine, natural bile salts are a potentially 120 
disruptive factor, causing irreversible degradation. However, when the objective is to adjust 121 
the dissolution rate of lipid nanoparticles in the intestine for the purposes of controlled drug 122 
release, bile salts can be of potential benefit when included as an excipient of the 123 
nanoparticle. A study by Oblich et al investigated the effect of different surfactants on the 124 
degradation rate of SLNs by lipase, and found that SLNs containing cholic acid sodium salt 125 
degraded around 50% more rapidly than SLNs containing poloxamer 407 [15]. This study 126 
suggested that SLN degradation rate in the intestine is adjustable by utilising the correct 127 
combination of surfactants, and that bile salts could be used to increase the rate of SLN 128 
breakdown. 129 
Digestion of food in the gut produces amino acids, di- and tri-peptides, lipids and 130 
carbohydrates which are potentially capable of binding to, and altering the properties of, 131 
nanoparticles [16]. Proteins are known to form together with nanoparticles to create coronas 132 
[17] although very few studies have looked at the formation of coronas made from food 133 
components. A study by Di Silvio et al showed that coronas were formed around magnetite 134 
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nanoparticles when co-incubated with digested bread in vitro, and furthermore that when 135 
these corona-nanoparticle complexes were isolated they were more readily taken up than 136 
corona-free particles into Caco-2 intestinal cells [18]. In a similar study by Lichtestein et al, 137 
poly (acrylic acid)-coated silver nanoparticles co-incubated with food digestion products (a 138 
mixture of proteins, fatty acids and carbohydrates) showed 40% higher accumulation in 139 
Caco-2 cells compared to when no food digestion products were included [19]. It conclusion 140 
from these in vitro studies is that food components can interact with nanoparticles, and this 141 
interaction can lead to alterations in nanoparticle physicochemical properties and their ability 142 
to accumulate in cells. The majority of in vitro nanoparticle cell accumulation studies do not 143 
take this factor into consideration, and this may be detrimental when developing 144 
nanoparticles for oral administration. 145 
 146 
3.2 The mucous of the gastrointestinal system 147 
The mucous layers of the body contain a complex mixture of carbohydrates, lipids, proteins, 148 
water, salts and biological debris. The most common constituents of mucous are mucin 149 
proteins 1-40 MDa in size, and the constituents, macro-rheology and micro-rheology of 150 
mucous has been extensively reviewed previously [20,21]. Mucous acts as a physical barrier 151 
against foreign particles, including pathogens, toxins and environmental particles, while 152 
allowing passage of selected gases, ions, nutrients, small molecules and certain proteins. The 153 
chemical attributes are similar for the various mucous layers present on the body [22], and the 154 
mucosal surfaces most relevant to current nanoparticle delivery research include those at the 155 
surfaces of the mouth, lungs, nasal passage, eyes, vagina and gastrointestinal system. This 156 
review focuses on the mucosal barriers of the gastrointestinal system, which includes the 157 
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distinct mucosal environments of the stomach, intestine and colon. However, other mucosal 158 
barriers are also occasionally referred to, due to relevant investigations on rheological and 159 
nanoparticle-interacting properties being performed on alternative mucosal sites and also due 160 
to the lack of research performed directly on gastric and intestinal mucous in humans. Of 161 
particular note, a number of studies have been conducted using cervico-vaginal mucous due 162 
to the relative simplicity of mucous collection. 163 
The mucous systems of the human stomach, intestine and colon have distinct attributes and 164 
functions, and exist in radically different luminal environments. The acidity of the contents of 165 
the human stomach is, at its highest, generally around pH 1.5-2 in fasted healthy subjects 166 
[23]. This level of acidity would damage an unprotected stomach wall, and indeed this 167 
clinical scenario leads to the formation of gastric ulcers [24]. To prevent this, the mucous in 168 
the stomach acts as an effective buffer zone and, combined with the excretion of neutralising 169 
bicarbonate molecules by the epithelial cells, results in a near-neutral pH adjacent to the 170 
apical cell surface of the stomach [25]. The stomach has a two-layered mucus system: the 171 
firmly-adherent mucous layer, which consists of transmembrane-spanning mucins of between 172 
100 and 500 nm in length [24], and the loosely-adherent mucous layer, which consists of 173 
much larger mucins of up to several micrometres in length and is not covalently attached to 174 
the gastrointestinal cells. The mucus, when subjected to shear force, forms a slippage plane 175 
between two surfaces with an unstirred layer immediately adjacent to the epithelial cell 176 
surfaces in the glycocalyx. The contents of the gut are coated by the shed mucous from the 177 
loosely-adherent mucous layer and are lubricated as they move along the intestine. The 178 
mucous layer of the small intestine is considerably thinner than the equivalent found in the 179 
stomach and large intestine, and this can be attributed to the small intestine being the primary 180 
site of absorption and that barriers impeding this process would be detrimental. The small 181 
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intestine also does not show a consistent two-layered mucous system as is found in the other 182 
regions [21], showing instead a consistent loosely-adherent layer but only sporadic patches of 183 
adherent layers. Glycosylation patterns present on the proteins of the small intestine mucous 184 
barrier mimic the glycosylation present on the cellular surface of the intestinal epithelium. 185 
Many bacteria bind naturally to glycosylated proteins for cellular entry, therefore the mucous 186 
acts as an alternative interaction site able to trap bacteria before cellular entry can be 187 
achieved [26]. In addition, small intestine mucous contains adsorbed lipids which can impede 188 
bacteria via non-specific hydrophobic bonding [27,28]. Trapped bacteria are then subjected to 189 
excreted antimicrobial molecules and can subsequently be shed back into the intestinal fluid 190 
along with the loosely-adherent mucous layer [29]. As with the stomach, the mucous system 191 
of the large intestine consists of a loosely-adherent and firmly-adherent layer. The thickness 192 
of the firmly-adherent layer is several hundred micrometers in humans, and is continually 193 
renewed from the epithelial cells with a half-life of around an hour [30]. The density of the 194 
firmly-adherent layer is very high, with the intention of keeping intestinal bacteria from 195 
reaching the epithelial cells. Conversely, the loosely-adherent layer of the large intestine is 196 
around 3-4 times less dense than the firmly-adherent layer, and is made to harbour the 197 
commensal bacteria. 198 
As mentioned previously, gastrointestinal mucous represents a potential barrier for 199 
penetration of large particles, and this includes nano-scale formulations designed to deliver 200 
therapeutic or diagnostic materials to the intestinal epithelial surface or the systemic 201 
circulation [31-35]. It must be accepted that, except in the cases where nanoparticles are used 202 
purely for luminal drug dissolution enhancement, nanoparticles will need to encounter the 203 
gastrointestinal mucous in some capacity. There is continuing research into the development 204 
of nanoparticles capable of interacting with the gastric and intestinal mucous, with mixed 205 
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success, and it is important to distinguish between muco-adhesive particles and muco-206 
penetrative particles, both of which will be discussed in this section of the review.  207 
 208 
3.2.1 Muco-adhesive nanoparticles  209 
As the name suggests, muco-adhesive nanoparticles are capable of adhering to mucosal 210 
layers of the body. There are two common rationales for using mucoadhesive nanoparticles of 211 
orally-administered therapy. Firstly, to increase the residence time of the particles at the site 212 
of absorption, which in the case of oral therapy is usually the small intestine. This is expected 213 
to increase the fraction of drug absorbed by allowing the intestinal absorption process to 214 
occur over a longer period.  Secondly, adherent particles can be used to target the treatment 215 
of local diseases of the stomach, intestine and colon. If an orally administered particle does 216 
not have the ability to adhere to mucous, it is likely to pass directly through the 217 
gastrointestinal tract without any significant contact with the epithelial cell layer [36]. 218 
Mucous can potentially bind to nanoparticles via various physicochemical mechanisms, 219 
hydrophobic interactions [37] and, in the case of cationic nanoparticles, via electrostatic 220 
impedance caused by anionic groups on mucins contained in the mucous [38]. In addition to 221 
these factors, the entanglements between mucins and other constituents create a “mesh” that 222 
can physically block particles larger than the mesh pore size. Although also influenced by 223 
surface chemistry and lipid exposure, endogenous and fabricated structures under 60 nm 224 
generally do not show impedance by mucous [39]. Instead, they are capable of passing 225 
through the barrier at speeds comparable to movement through water following Brownian 226 
diffusion theory, provided that the molecules do not interact physicochemcally with the 227 
mucous [40]. To investigate this further, Olmsted et al measured virus movement through 228 
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mucous and found that Norwalk virus (38 nm) and human papilloma virus (HPV) (55 nm) 229 
both diffused in human cervical mucus at the same rate as they do in water, whereas herpes 230 
simplex virus (180 nm) moved through human cervical mucus around 1000-fold slower than 231 
through water. In a study investigating the movement of nanoparticles through porcine 232 
intestinal mucous, pore size was determined using electron microscopy to be 211 ± 7 nm, and 233 
nano-sized latex beads above this size were unable to pass through the mucous [41]. These 234 
restrictions to macromolecule movement through mucous have led some researchers to 235 
conclude that nanoparticles above a certain size will not be able to traverse the intestinal 236 
mucous barrier intact. Confusingly, a study has been reported where larger 237 
nanopartlesparticles (200 nm and 500 nm) were able to overcome the mucous pore size 238 
limitation when particles were coated with polyethylene glycol [42]. Indeed these larger 239 
particles showed around 50-fold improved cervicovaginal mucous penetration when 240 
compared to 100 nm particles that lacked the polyethylene glycol coating. This indicates that 241 
mucous pore size is a potential limiting factor for absorption of larger particles, but that 242 
methods other than particle size reduction may be available to overcome this issue, 243 
potentially by altering the pore sizes present in the mucous.  244 
Nanoparticles movement through the mucous barrier can also be impeded by mucous 245 
shedding. If nanoparticles adhere to the loosely-adherent mucous layer they risk rapid 246 
clearance, as this layer is continuously being shed and replaced from the stomach and 247 
intestine surface. To investigate this, Tirosh et al investigated the migration of adhesive 248 
(polycarbophil) and nonadhesive (Eudragit RL-100) particles in the rat intestine and found no 249 
difference in retention times [43]. The adhesive particles predominantly bound to the loosely-250 
adherent mucous layer, and were found to be coated in mucous “plugs” following discharge 251 
from the perfused rat jejunum. To overcome this phenomenon, particles in other studies have 252 
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been designed to naturally adhere to the firmly-adherent mucous layer, which resides below 253 
the loose layer and is not readily shed. Particles synthesised from common polymers, such as 254 
polylactic acid (PLA), polylactic-co-glycolic acid (PLGA) and polyacrylic acid (PAA) are 255 
able to adhere to the intestinal mucous via hydrophobic interactions, hydrogen bonding, 256 
entanglement, or more commonly a combination of these factors [32]. The exact influences 257 
that particle properties have on mucous interactions are still poorly understood but are worthy 258 
of investigation to further validate and optimise this delivery strategy.   259 
 260 
3.2.3 Muco-penetrative nanoparticles  261 
Considering the complications associated with using muco-adherent nanoparticles, research 262 
has been undertaken to create muco-penetrative particles capable of traversing the mucous 263 
layer and reaching the epithelial layer intact. Attempts have been made to design mucous-264 
penetrating nanoparticles containing “mucous permeation enhancers”, also known as 265 
mucolytic agents, capable of degrading the mucous layer, in a process analogous to that used 266 
for treatment of cystic fibrosis [33]. This strategy is particularly useful for allowing access of 267 
peptide-based treatment to the epithelial cell layer, and has been reviewed previously [44]. 268 
Another strategy used to create mucous-penetrating nanoparticles is to coat particles with 269 
“stealth” excipients which avoid mucous interactions. In mouse studies, vaginal mucous 270 
penetration of carboxylic acid–coated, fluorescent polystyrene nanoparticles was increased 271 
when particles were coated with polyethylene glycol, and the extent of mucous penetration 272 
was greater when the polyethylene glycol was of a shorter chain length and was more densely 273 
packed on the particle surface [45]. The authors hypothesised that the longer polyethylene 274 
glycol chains were physically restricting the movement of the particles through the mucous. 275 
Encouragingly, the particles coated with polyethylene glycol had a longer residence time in 276 
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the vaginal mucous than did the conventional particles. Furthermore, particles coated with 277 
polyethylene glycol which contained acyclovir protected 53% of mice from artificially 278 
introduced HCV-2 infection, compared to only 16% protected by soluble acyclovir. In a 279 
separate study, bovine serum albumin was used to coat silicon oxide nanoparticles and this 280 
was shown to reduce the interactions of the particles with mucous derived from cow 281 
submaxillary glands [46]. Bovine serum albumin is a negatively-charged macromolecule and 282 
it was hypothesised that this would reduce electrostatic interactions with the similarly 283 
negatively-charged mucins present in the mucous. Although these studies emphasise the 284 
potential of mucous-penetrating nanoparticles for improving treatment delivery, these studies 285 
focussed on mucous located at the site of the vagina and the submaxillary glands, 286 
respectively, and further investigations are required to establish whether this strategy of 287 
penetrating mucous is viable in the intestinal environment. Of note, the optimal properties 288 
that are emerging for designing a muco-penetrative particle (dense, hydrophilic coat and 289 
negative charge) are unlikely to suit nanoparticles which require to be endocytosed into the 290 
intestinal epithelial cells. 291 
Many investigations have been undertaken to develop improved treatments for Helicobacter 292 
pylori (H. pylori) gastric infection and this provides a good case study for the development of 293 
both muco-adhesive and muco-penetrative nanoparticles for treating localised mucosal 294 
infections. H. pilori is a Gram negative bacteria associated with 95% of duodenal ulcers, 80% 295 
of stomach ulcers and an increased risk of the development of stomach cancer in humans [47-296 
49]. H. pylori resides predominantly within the stomach, where it shrouds itself deep within 297 
the firmly-adherent mucous layer and is capable of attaching to gastric epithelial cells [50]. 298 
One of the key barriers that the bacteria must overcome to achieve this is to penetrate the 299 
gastric mucous. It achieves this by producing urease, which catalyses hydrolysis of gastric 300 
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urea to yield ammonia and carbon dioxide, thus elevating the pH of its gastric environment. 301 
This pH elevation also induces a dramatic decrease in the viscoelastic properties of the gastric 302 
mucous, allowing the bacteria to travel freely towards the gastric epithelial surface [51]. 303 
Current therapy for H. pylori eradication consists of a triple-drug regimen including two 304 
antibiotics (clarithromycin combined with either metronidazole or amoxicillin) and a proton 305 
pump inhibitor [52]. Eradication success is not high, with nearly 25% of patients showing 306 
continued infection despite treatment [53]. It can be hypothesised that treatment failure 307 
occurs due to a possible combination of factors that are unfavourable to drug action, such as 308 
the development of drug resistance, the high acid environment and low residence time within 309 
the target organ (the stomach), and the presence of a large, dense mucous layer protecting the 310 
bacteria from stomach contents [54]. As such, it has been hypothesised that a formulation 311 
able to deliver drugs into the gastric mucous for maximum and prolonged local exposure, 312 
whilst protecting the drug from the acidic pH, would constitute an optimal oral treatment for  313 
H. pylori (Figure 1a and 1b). Several delivery mechanisms have been investigated for 314 
improving treatment, including floating tablets [55], microspheres [56], beads [57], gels [58], 315 
and nanoparticles (Table 2). Muco-adhesive nanoparticles have been developed to increase 316 
the residence time of antibiotics in the stomach, thus increasing the likelihood of bacterial 317 
eradication [59-61]. More recently, Thamphiwatana et al designed nano-scale (around 100 nm 318 
with a zeta potential of -54 mV) liposomal linolenic acid (lipoLLA) residues for eradication 319 
of H. pylori [62]. Results demonstrated that liposomes readily attach to H. pylori in vitro. 320 
When mice were orally administered 1.2 mg of fluorescently labelled lipoLLA, around 6% 321 
and 3% of the dose was retained within the mucous of the stomach four hours and twenty 322 
four hours post dose, respectively. These data also demonstrated a significantly improved 323 
antimicrobial efficacy of LipoLLA in reducing H. pylori bacterial load in mouse stomach 324 
compared with other treatment regimens, including the standard triple therapy. Muco-325 
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penetrative nanoparticles have been created using chitosan and either heparin [63] or sodium 326 
alginate [64] to allow a system of reaching the bacteria at the gastric epithelial surface. Other 327 
studies have been undertaken to optimise H. pylori treatment by encapsulation of multiple 328 
treatments in one particle [65] and the development of nanoparticles with pH-responsive 329 
degradation [63]. All such design projects need to consider how particles interact with the 330 
gastric mucous, which remains the crucial target site and this remains an exciting area of 331 
exploration with the potential to also uncover novel mechanisms and modalities for treatment 332 
of diseases both within the gut and systemically.  333 
 334 
3.3 The intestinal epithelial cell barrier 335 
The small intestine has a large surface area estimated at 30-300 m2 [2] whereas the large 336 
intestinal has considerably lower surface area due to the lack of microvilli, which suggests 337 
that the absorption of nanoparticles is more likely to occur at the small intestinal surface. The 338 
epithelial cells of the small and large intestine predominantly consist of absorptive 339 
enterocytes, with mucous-secreting goblet cells and other immunological and hormone-340 
producing cells also present at lower levels. Microfold cells (M cells) are also present on the 341 
intestinal epithelium and usually cluster together to form Peyer’s patches. M cells allow for 342 
the uptake of particles directly into the immunological system of the gut [66]. Once intact 343 
nanoparticles have passed through the mucous layers surrounding the intestinal wall, particles 344 
must either remain within the mucous, spontaneously break down to release contents, or be 345 
able to penetrate the epithelial cells barrier. As is the case for all intestinally-absorbed 346 
substances, nanoparticles penetrate the epithelial cell barrier by either the transcellular 347 
(through the cell) or paracellular (between cells) pathways. Sections 3.3.1 to 3.3.3 investigate 348 




3.3.1 The permeability of the cell membrane and tight junctions 351 
Bile salts, in addition to their ability to promote solubilisation of lipid-based nanoparticles in 352 
the intestinal fluid [67]. It has been demonstrated that bile salts enhance the epithelial 353 
transport of hydrophilic drugs via the paracellular route and that of hydrophobic compounds 354 
via both the paracellular and transcellular routes [68]. The mechanisms by which bile salts 355 
achieve this are not fully understood, but investigations have suggested that bile salts can 356 
interact with membrane-bound phospholipids and incorporate with the cell membrane to form 357 
hydrophilic reverse micelle pores [67], can bind to calcium channels which control the 358 
paracellular route [69], and can inhibit the activity of membrane-bound drug efflux 359 
transporters [70].  360 
Tight junctions are multi-protein complexes which form a physical, selectively impermeable 361 
seal between the cell of the epithelium of biological barriers, including the gastrointestinal 362 
system [71]. Four key proteins have been identified in the formation of tight junctions: 363 
junctional adhesion molecule [72], tricelluin [73], occuldin [74], and members of the claudin 364 
family [75]. The junctions are expressed at the apical pole of the epithelial cells and act as a 365 
barrier to the diffusion of solutes through the intercellular space and recruit various 366 
cytoskeletal as well as signalling molecules at their cytoplasmic surface. Additionally, the 367 
junctions are able to impede the paracellular transport of macromolecules, including 368 
nanoparticles. To overcome this barrier, certain substances have been tested to reversibly 369 
open tight junctions, temporarily allowing movement of macromolecules between the cells 370 
and giving direct access to subepithelial tissue and blood vessels. Sonaje et al found that 371 
chitosan nanoparticles increased the paracellular movement of insulin through a Caco-2 372 
monolayer [76]. Tight junction opening was confirmed by staining the intracellular space 373 
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with lanthanum and it was shown that tight junctions closed rapidly following removal of 374 
chitosan. Importantly, these observations were confirmed in an animal biodistribution study. 375 
Other studies have shown similar results using chitosan nanoparticles [77], suggesting that 376 
chitosan represents a safe permeation enhancer and is a potentially effective carrier for oral 377 
protein delivery. 378 
 379 
3.3.2 Endocytosis and exocytosis mechanisms 380 
Endocytosis is a general mechanism found in all cells that transport membrane proteins and 381 
extracellular material in membrane vesicles into the cell interior [78]. The endocytic 382 
pathways consist of two distinct mechanisms: phagocytosis, which occurs only in certain 383 
immunological cells, and pinocytosis, which can occur in virtually all mammalian cell types 384 
and is most likely the dominant endocytic mechanism involved in particle uptake in the 385 
intestinal epithelium. Pinocytosis, or the process of “drinking” particles into the cell, is 386 
further divided into clathrin-mediated, caveolae-mediated, independent and macro 387 
pinocytosis, as shown in Figure 2 (reviewed in [78,79]). Each of these mechanisms appearing 388 
to have non-synonymous preferences of particle size, charge, shape, modulus and surface 389 
chemistry [80]. However, the extent and mechanisms of endocytosis of each particulate 390 
delivery system into cells, including into the enterocytes of the intestinal epithelium, is still 391 
poorly understood and still require investigation on a case-by-case basis. Recent 392 
investigations into the endocytosis of nanoparticles are given in Table 3. Following 393 
endocytosis into the intestinal epithelial cells, nanoparticles can either remain inside the cell 394 
unchanged, break down to release their contents intracellularly, or undergo exocytosis 395 
(Figure 2). If the objective is that internalised nanoparticles reach the systemic circulation 396 
intact, it is essential that particles are exocytosed from the basolateral membrane of the 397 
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epithelial cell. However, despite its importance there has been little effort made to investigate 398 
the exocytosis of nanoparticles. Receptor-mediated transcytosis is a process where vesicular 399 
transport of macromolecules can occur from one side of a cell to the other, and is mediated by 400 
ligand-receptor interactions. Importantly, receptor-mediated transcytosis avoids the 401 
intracellular degradation and recycling stages present in other endocytic pathways. Lectins 402 
are a group of carbohydrate-binding proteins known to be involved in cell recognition and 403 
adherence processes, and this property has led to the development of lectin-conjugated 404 
nanoparticles for targeted oral drug delivery [81-83]. Other ligands have been similarly 405 
utilised for delivery of both drugs and gene therapies, such as invasions [84]. A potential 406 
issue found with the active targeting approach is that the ligand-bound particles appear to 407 
have a reduced ability to diffuse across the mucous layer [85,86]. At present, no orally 408 
administered nanoformulation has been accepted for clinical use which has also been shown 409 
to reach the systemic circulation intact. Therefore, investigators should determine if oral 410 
administration is a feasible approach to delivering intact nanomedicines to the systemic 411 
circulation, or if simpler methods (ie intravenous or intramuscular injection) are preferred. 412 
 413 
3.3.3 M-cell-mediated transcytosis  414 
M cells are specialized epithelial cells which transport antigens from the intestinal lumen to 415 
cells of the immune system: soluble macromolecules, small particles, and even entire 416 
microorganisms are transported via this route. The reasons for this process are to initiate an 417 
immune response in the case of harmful organisms and to develop a tolerance in the case of 418 
food antigens [87,88]. M cells are concentrated in specific regions of the intestinal epithelium 419 
called Peyer’s patches, of which there are around a few hundred in the ileum of adults and a 420 
decreasing number with increasing age [89] 421 
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As M cell-mediated transcytosis is capable of transporting larger molecules and is also able to 422 
bypass lysosomal degradation, there have been attempts to exploit this route for enhancing 423 
nanoparticle cellular uptake. To demonstrate this in vitro, increases in monolayer permeation 424 
of over one thousand-fold have been observed in studies measuring movement of 200-500 425 
nm polystyrene particles, when cell monolayers have been altered to include M cells [90]. 426 
Emerging literature is demonstrating the importance of certain material characteristics for 427 
effective targeting of particles to Peyer’s patches. For example, a particular suitability of 428 
neutral particle charge [91] and the enhanced uptake observed following the coating of 429 
particles with proteins derived from intestinal bacteria [92,93]. The endogenous process of 430 
M-cell-mediated pathogen uptake has been exploited by producing vaccines coupled to 431 
cholera toxin [94]. These chitosan-bound particles were more readily transcytosed by M cells, 432 
via the ganglioside GM1 receptor. Another example of exploiting the endogenous role of M-433 
cells is the use of yeast capsules containing nanoparticles [95]. 434 
Uniquely in the gut, M cells provide an exploitable access route to the gastrointestinal-435 
associated lymphoid tissue (GALT), thus bypassing the requirement of particles to enter the 436 
portal vein and undergo first-pass liver clearance before reaching the systemic circulation. It 437 
is not fully understood how this would affect the distribution of nanoparticles, and further 438 
investigations are required to determine if, for orally administered nanoparticles, the GALT is 439 
a more desirable entry point than the portal vein. Despite encouraging results in vitro, there 440 
has been limited success in exploiting M cell-mediated nanoparticle transcytosis in humans. 441 
Firstly, there are a very limited number of Peyer’s patches in the human gut [89] and the total 442 
number of M cells on the intestinal surface is estimated at only one millionth the number 443 
compared to other epithelial cells [96]. Secondly, the maximum kinetic activity of an 444 
individual Peyer’s patch is potentially too low for exploitation. As the primary role of M cells 445 
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is to sample gut contents and not to act as a large-scale transportation route for 446 
macromolecules, transcytosis capacity is expected to be low. This was emphasised in a study 447 
by Pappo et al, which investigated the uptake of polysetyrene nanoparticles by individual 448 
Peyer’s patches from rabbit intestine. The study found that the activity of all combined 449 
patches only led to 0.02% of the nanoparticles being internalised [97]. Thirdly, it is not clear 450 
whether nanoparticles are efficiently transported from the Peyer’s patches to the systemic 451 
circulation. Polystyrene nanoparticles have been found to be associated with dendritic cells at 452 
the Peyer’s patches up to fourteen days, following uptake into the patches [98]. 453 
 454 
4. Limitations in using in vitro and in vivo models in nanoparticle 455 
oral absorption studies 456 
Once nanoformulations have been created and are ready for assessment in vitro, it is 457 
important to assess the degradation rate of formulations in a variety of biologically relevant 458 
matrices. In addition to this, there are several in vitro methods that have been developed to 459 
assess cell membrane permeation which are directly relevant to intestinal absorption. A 460 
simple high-throughput screening technique is the parallel artificial membrane permeability 461 
assay (PAMPA), where drug movement through a lipid-infused artificial membrane is 462 
measured. Different lipid combinations can be utilised, including more complex layers 463 
consisting of phospholipids [99]. Using PAMPA does come with disadvantages such as the 464 
absence of drug transporting proteins and, particularly relevant for nanoparticles, the absence 465 
of endocytosis mechanisms and a mucous layer. Several cell line-based systems are available 466 
to assess for potential intestinal permeability of compounds, including the measurement of 467 
drug movement through single layers of MDCKII cells or, more commonly in drug 468 
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discovery, Caco-2 [100] cells cultured on permeable supports. The Caco-2 monolayer 469 
permeability system includes intestinal drug transporter expression, although to varying 470 
levels compared to in vivo expression [101], and has been demonstrated to allow for 471 
endocytic pathway-mediated cell entry [102], and therefore provides a more realistic scenario 472 
than PAMPA when screening drugs. However, this system is potentially unsuited to 473 
screening nanoparticle movement across a cell monolayer. Firstly, Caco-2 cells do not 474 
produce a mucous layer. Secondly, no M cells are present on a Caco-2 monolayer. As 475 
explained in the previous section, the mucous layer provides a potential barrier to large 476 
particles entering the intestinal epithelial cells, and M cells allow access of large particles into 477 
Peyer’s Patches. In an attempt to address these issues, a more complex “triple culture” system 478 
has been developed. In this system, HT29-MTX cells, which produce a mucous layer on their 479 
apical surface, are seeded alongside Caco-2 cells to form a mixed population monolayer. 480 
Additionally, RajiB immunological cells can be introduced to the basolateral chamber, 481 
resulting in differentiation of a proportion of Caco-2 cells to M cells. This system has been 482 
used to investigate the effect of polystyrene particle size on cellular permeation potential 483 
[103]. 484 
When investigating nanoparticle-induced tight-junction opening in vitro, Caco-2 cells 485 
monolayers are a commonly used model [104]. However, Caco-2 cells do not express the 486 
exact set of proteins associated with tight junction formation in vivo [105]. Of note, claudin-5 487 
is present in human jejunum tight junctions and claudin-8 is present in human large intestine, 488 
but neither proteins are expressed in Caco-2 cells. Linnankoski et al compared the porosity 489 
and pore size of tight junctions in human intestinal wall and in commonly utilised epithelial 490 
cell lines used to represent the intestinal epithelium [106]. Compared to intestinal tissue tight 491 
junctions, Caco-2 and MDCK-II cells both showed smaller tight junction porosity and 2/4/A1 492 
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cells showed larger pore size. The effects of these differences are unknown but it should be 493 
acknowledged that the tight junctions formed by commonly used cell lines may not fully 494 
represent those found in vivo.  495 
The pancreatic enzymes present in the intestinal fluid are often not included during in vitro 496 
assessment of nanoparticle Caco-2 uptake experiments, even though these enzymes have the 497 
potential to break down nanoparticles. To avoid this issue, physiologically-relevant intestinal 498 
buffers can be created which include pancreatic enzymes [107]. Simulated intestinal fluid 499 
(SIF) is described in the USP and contains pancreatin at 10 mg/mL, whereas other commonly 500 
used intestinal buffers such as fasted state simulated intestinal fluid (FaSSIF) and fed state 501 
simulated intestinal fluid (FeSSIF) contain no enzymes. In addition to the luminal enzymes, 502 
the enterocytes of the small intestine express multiple digestive protease enzymes which are 503 
active at the apical surface and are potentially relevant to peptide-containing-nanoparticle 504 
stability. Caco-2 cells show no or poor expression of several of these protease enzymes, as in 505 
the cases of transmembrane protease serine 4 and dipeptidyl-peptidases 4 [108] and therefore 506 
any interactions between these enzymes and nanoparticles will be poorly represented in in 507 
vitro studies utilising Caco-2 cells. 508 
In vitro models are beginning to be established to investigate many aspects of orally absorbed 509 
nanomedicines and their interactions with intestinal mucous. However, current in vitro 510 
systems cannot fully replicate the complexities observed in vivo. In order to breach the gap 511 
between in vitro models and clinical application, assessment in pre-clinical species is 512 
required. Despite the advantages of using a more complex biological system, there are 513 
inherent difficulties in extrapolating data from pre-clinical species to predictions in human. 514 
The gastrointestinal tract, when compared between species, have shown significant 515 
differences, such as in pH [109] and transit time [110]. There is also significant variation in 516 
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the lymphoid structures present in the GI tract. Lymphocyte-filled villus are present in human 517 
and rat whereas cryptopatches are only found in mice [111]. Rodents do not produce 518 
intestinal mucin to the same extent as is observed in humans, and this most likely reduces the 519 
barrier properties to successful drug delivery and nanoparticle distribution [112]. 520 
Additionally, rodents have a significantly higher density of Peyer’s patches in the intestine 521 
when compared to humans and this should be considered when optimising oral absorption via 522 
this pathway [113]. In addition to anatomical differences, there are important variances 523 
between species in the expression and/or activity of metabolic enzymes and transporters 524 
relevant to intestinal absorption [114-117]. 525 
 526 
5. Conclusions 527 
There exist great possibilities for nanotechnologies to develop controlled and targeted drug 528 
delivery systems by exploiting the anatomical, physiological and molecular processes at the 529 
gastrointestinal mucosal surface. However, progress has been slow, better mechanistic 530 
understanding is required, and as a result no nanotechnology-enabled products are currently 531 
in clinical use which specifically target the mucous layers of the stomach or the intestine. 532 
Similarly, no orally-administered nanoparticles clinically in use have been designed to allow 533 
the particle to gain entry to the systemic circulation intact. Compared to small molecules, the 534 
relationship between nanoparticle characteristics and intestinal absorption potential are 535 
poorly understood. In order to inform future design strategies, further investigations in this 536 
area are warranted and will improve our understanding of any relationships which can be 537 
utilised for addressing treatment and bioavailability goals. 538 
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Ideally, oral nanoformulations which aim to gain entry to the systemic circulation will be able 539 
to avoid being degraded in luminal environment, avoid being trapped and cleared by the 540 
loosely-adherent mucous layer, will be able to penetrate the mucous to reach the intestinal 541 
surface where transcytosis of the particle can then take place. Alternative routes past the 542 
epithelial cells, such as paracellular movement and via M-cells, also exist. When the desired 543 
outcome is local release of drug at sites along the gastrointestinal system, such as is the case 544 
with H. pylori eradication, adherence of nanoparticles to the firmly-adherent mucous layer 545 
would be advantageous, as would a controlled release strategy. Many global research efforts 546 
are now focused upon harmonising progress from technology development and disease 547 
understanding, and an inter-disciplinary approach to development in this area is warranted. 548 
 549 
6. Expert Commentary 550 
Despite the potentially large clinical advantages and continued research activity in the 551 
development of nanotechnology-based oral drug delivery products, it cannot be ignored that 552 
there has been a disappointingly small number of new products that have progressed to use in 553 
humans. Furthermore, all oral nanomedicines currently used in clinical therapy are SDNs 554 
with the objective of improving the dissolution rate of poorly soluble drugs. The 555 
immunosuppressant sirolimus, which has very low aqueous solubility, is available as an oral 556 
solution but also as an SDN tablet (Rapamune®, licenced 1999 in USA, 2001 in EU). The 557 
tablet is generally preferred for ease of use and exhibits a ~20% increase in oral 558 
bioavailability compared with the oral solution, with potential for further improvements on 559 
the current formulation [118]. In a similar scenario, the antiemetic aprepitant has very low 560 
solubility at low pH and oral administration of traditional formulations shows poor 561 
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bioavailability and high inter-patient pharmacokinetic variability. An SDN formulation of 562 
aprepitant (Emend®, licenced in 2003) was created and resulted in an improved oral 563 
absorption. Food intake can result in altered and/or variable drug absorption, and SDN 564 
formulations have been developed to negate this effect in the cases of the antihyperlipidemic 565 
fenofribate (Tricor®, licenced in 2004) and the anticancer drug megestrol acetate (Megace® 566 
ES, licenced in 2005).  567 
To rectify this situation, the authors believe that several developmental barriers exist which 568 
need to be addressed, such as the lack of validated in vitro assays for assessing 569 
nanoformulation pharmacokinetics, the unsuitability of standard in vivo intestinal absorption 570 
models, the lack of interest from companies to reformulate potentially unprofitable generic 571 
treatments, poor scientific understanding of the technology, and the difficulty in convincing 572 
regulatory bodies of the safety of intestinal mucous-targeting and mucous-altering 573 
nanomedicines. Regarding the issue of safety, a primary role of mucous is to protect exposed 574 
surfaces from foreign entities, and very little is known about how orally administered 575 
nanoformulations can affect this role. In an ex vivo experiment using human cervicovaginal 576 
mucous, Wang et al found that the level of mucous penetration of 1 µm muco-inert particles 577 
was increased ~10-fold following pre-treatment of the mucous with 200 nm mucoadhesive 578 
nanoparticles [119]. The authors hypothesised that the mucoadhesive particles were eliciting 579 
this effect by bundling mucin fibers together through polyvalent adhesive interactions, and 580 
suggested that this may lead to greater exposure of mucosal cell barriers to foreign particles, 581 
including pathogens and other potentially toxic nanomaterials. In addition, mucous 582 
penetrating nanoparticles, which actively degrade mucous, are likely to have a similar effect. 583 
Indeed, this has been demonstrated in vivo. N-acetyl-L-cysteine (NAC), a commonly used 584 
mucolytic agent, was apparently shown to cause a 6-fold increase in the absorption of 3.2 μm 585 
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polystyrene particles in both the Peyer's patches and mesenteric lymph nodes in a ligated rat 586 
intestine model [120], although this data does not support the belief that M cells can only 587 
endocytose particles of around 1 µm in size and below [121]. In another study, a 30% 588 
depletion of mucus by pilocarpine in an ex vivo rat intestinal absorption model showed a 3-589 
fold increase in E. Coli translocation [26]. If this were to translate to an increased infection 590 
risk in humans, there would be serious safety issues concerning the use of mucous-targeting 591 
nanoparticles which has remained relatively unaddressed in current studies. Of particular 592 
concern would be the use of mucous-targeting treatments in immune-compromised patients, 593 
such as in the use of anti-HIV drugs and cancer chemotherapy. Future research should be 594 
undertaken to investigate this risk, and to understand whether it is possible to use mucous-595 
targeting particles to improve oral medicine delivery without increasing exposure of the 596 
intestinal surface to pathogens present in the intestine. 597 
 598 
7. Five-year view 599 
Ideally, within five years it is feasible that a mucous-targeted and potentially mucous-600 
modifying nanoformulation will have been accepted for clinical use by the relevant 601 
regulatory bodies. There will be additional trials investigating the use of SDNs and other 602 
nanoformulations for improving the dissolution and bioavailability of poorly soluble drugs, as 603 
this remains the only strategy that has led to clinically accepted oral nanomedicines. A recent 604 
example is the success of using SDN reformulation to increase the bioavailability of the 605 
antiretrovirals lopinavir and efavirenz in animal studies [4,122] which is now being assessed 606 
in Phase 1 trials. Through improved assay design and large scale screening programmes, 607 
there will be an increased understanding of how the physicochemical properties of 608 
27 
 
nanoparticles affect mucous binding and endocytosis. General “design rules” are currently 609 
being established which will only become more sophisticated over time [37]. Improvements 610 
in technology, such as in the use of “lab-on-a-chip” microfluidic set-ups, will potentially help 611 
to increase the predictive ability of in vitro experiments to measure movement of 612 
nanoparticles across the gut [123,124]. Similarly, the growing wealth of information 613 
regarding the influence that physicochemical characteristics play on nanoparticle 614 
biocompatibility and safety is allowing improved design and rationale for their development 615 
and preclinical assessment. From all this, a start is being made in establishing standard rules 616 
which associate nanoparticle characteristics with toxicity, including immunological issues 617 
[125]. 618 
 619 
8. Key highlights 620 
• Nano-scale oral formulations are being developed to allow delivery of poorly 621 
absorbed medicines such as peptides, macromolecules and certain small drug-like 622 
molecules. 623 
• The mucous layer of the gastrointestinal tract is capable of trapping pathogens and 624 
eliminating large particles, including nanoparticles, as part of the natural defence 625 
system of the body. 626 
• The interactions between nanoformulations and the gastrointestinal mucous layer are 627 
poorly understood. 628 
• Nanoformulation properties such as particle size, charge, and shape, as well as 629 
mucous properties such as viscoelasticity, thickness, density, and turn-over time are 630 
all relevant to these interactions but definitive design rules have not been established. 631 
28 
 
• In vitro and animal models traditionally used in drug development are often 632 
unsuitable for assessing the potential of nanoparticles to enhance the oral 633 
bioavailability of treatment. 634 
• Research should focus on developing reliable screening methods which take into 635 
consideration the influence of the intestinal mucous on nanoparticle absorption 636 
• A goal of this research should be the establishment of a “design blueprint” for 637 
nanoparticles that are capable of traversing the gastrointestinal epithelium, hence 638 
enabling oral delivery of drugs that are currently poor oral absorption or are limited to 639 
administration by injections. 640 
• The ultimate goal is that absorption-enhancing nanoformulations will be accepted into 641 
the drug market. 642 
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Stomach 1.3 46.56 NA 0.25 75-170 97-158 
Duodenum 6 41.56 1.53 0.26 16 ± 3 154 ± 39 
Jejunum 6.2-6.4 276.5 1.29-1.45 1.67 15 ± 2 108 ± 5 
Ileum 6.6-7.4 214.65 0.82-1.13 1.29 29 ± 8 447 ± 47 
Colon 6.8-6.8 97.82 2.41-3.39 16.76 116 ± 51 714 ± 109 
Table 1. Physiological characteristics of the sections of the gastrointestinal system. The pH, 1013 
volume, radius and transit time data are the data used in the GastroPlus physiologically based 1014 
pharmacokinetic modelling software for simulated fasted human subjects [126]. The 1015 
thickness of loosely and firmly adherent mucous was obtained from rats [127] and is a meta-1016 
analysis of several studies giving the mean thickness ± standard deviation or, in the stomach, 1017 
thickness range. 1018 
 1019 
Excipients Drug Notes Reference 
Muco-adhesive nanoparticles    
Ethyl cellulose, methyl cellulose α-mangostin Controlled drug release at 
higher pH 
[59] 
Poly (lactic-co-glycolic acid) Clarythromycin, 
acetohydroxamic 
acid 
Enhanced in vitro H. pylori 
kill 
[60] 
Poly (lactic-co-glycolic acid) Clarythromycin Equal or enhanced 
eradication effect against 
clinical H. pylori strains  
[61] 
Chitosan, alginate  Pexiganan Greater gastric mucous 
retention and effectiveness 
in rodent model 
[128] 
Chitosan, alginate, gelatin, Poly-ƴ-
glutamic acid 
Amoxicillin Increased drug stability in 
low pH 
[129] 
Targeted nanoparticles    









Montmorillonite, polyethyleneimine Metronidazole Disrupts H. pylori 
membrane, improved 
effectiveness in rodent 
model 
[131] 
Ureido-conjugated chitosan Amoxicillin Targeted to H. pylori urea 
transporter 
[132] 
Lpp20 antigen, myristic acid None  Lpp20 used as template to 
imprint nanoparticle 
surface and encourage 








and targeting of bacteria 
[134] 
Muco-penetrative Nanoparticles    
Chitosan, heparin None Can penetrate mucous to 
reach bacteria 
[63] 
Chitosan, alginate Amoxicillin Long-term mucous 
penetration confirmed 
using fluorescent labelling 
[64] 
Table 2. Examples of nanoparticles created to target H pylori infection by employment of 1020 
various design strategies. Strategies occasionally overlap, although, roughly categorise into 1021 
the adherence to gastric mucous to prolong drug exposure, the targeting of the bacteria or of 1022 
















Nanoparticle Size (dm) Surface Charge Cell Types Summary Reference 
Polystyrene NPs 40 & 200 nm 
 
Can be easily 
synthesised 
into a broad 






Cervical cancer cell 
line (HeLa) 
 




cell line (1321N1) 
 
Endocytosis of polystyrene NPs are 
mostly caveolin-mediated & clathrin-
mediated. Mouse macrophage, cervical 
cancer, lung carcinoma and the brain 
astrocytoma cell lines also utilise 
micropinocytosis, phagocytosis, 
microtubule cytoskeleton and actin 
polymerisation mechanisms.  
 
Due to their ease of synthesization in a 
broad range of sizes, polystyrene NPs are 





Vitamin E-loaded OAE NPs 50, 120, 420 
and 730 nm 
Negative Caco-2 cell line 
 
Excised rat jejunum 
 
OAE NP endocytic mechanisms are 
clathrin-mediated and caveolae-mediated 
endocytosis and micropinocytosis based. 






150 nm Negative Folate-receptor-
overexpressing 
cancer cells (KB 
cells) 
Folate receptor–mediated endocytosis is 











mediated endocytosis and 
macropinocytosis are the main 
mechanisms of CS NP cellular uptake. 
 
[140] 




kidney cell line 
 
In comparison to CS NPs, mannosylated 
CS NPs can target macrophages and enter 










carcinoma cell line 
(EC109) 
 
CS/HA-g-PCL NPs target tumour cells and 
enter via CD44 receptor-mediated 
endocytosis. 
[142] 
PR9/QD complexes 100 nm Positive Lung carcinoma cell 
line (A549) 
 
Endocytic inhibitors were used to show 
that PR9/QD complexes enter the cell via 
classical endocytosis such as caveolae-






SNA NPs 10 nm Negative Endothelial cell line 
(C166) 
 









The 3D oligonucleotide shell promotes 
the entrance of SNA NPs into cells via 
lipid-raft–dependent, class A scavenger 
receptor-mediated and caveolae-





13 and 50 
nm spheres, 
and 40 nm 
stars 
Negative Glioblastoma cell 
line (U87) 
After 24-hour incubation 13nm spherical 
AuNPs remained dispersed within 
endocytic vesicles whilst 40nm star and 
50nm sphere AuNPs did not. Although 
the specific endocytic pathway was not 
determined, the suitability of 40 and 




FBS-coated AuNPs 20nm - Lung fibroblasts 
(MRC5) 
Endocytic inhibitors demonstrated that 





Chang liver cell line 
 




Table 3. Investigations into the endocytosis of various nanoparticles. Abbreviations: Au, 1035 
gold; CS, chitosan; CS/HA-g-PCL, chitosan coated polycaprolactone-grafted hyaluronic acid; 1036 
dm, diameter; FBS, fetal bovine serum; nm, nanometer; NPs, nanoparticles; OAE, oleoyl 1037 
alginate ester; PR9, cell-penetrating peptide; QD, quantum dot; QGY, hepatocellular 1038 
carcinoma cell line; siRNA, small interfering ribonucleic acid; SNA, spherical nucleic acid. 1039 
 1040 
